Selective feticide as a treatment of severe preeclampsia in discordant twins.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 19 01 2019
revised: 27 06 2019
accepted: 05 09 2019
pubmed: 10 9 2019
medline: 11 11 2020
entrez: 10 9 2019
Statut: ppublish

Résumé

Multifetal gestation is often complicated by the development of preeclampsia. In some twin gestations, preeclampsia develops in association with restricted fetal growth of only one fetus. Instead of termination of the entire pregnancy, we investigated an alternative approach to the management of such pregnancies that might allow unharmed survival of the normal twin. We present a case of preeclampsia in twin discordance with severe fetal growth restriction at 25 weeks of gestation. Preeclampsia was linked to a lethal condition in one twin and was treated with selective feticide in an effort to reverse preeclampsia. Inasmuch as the fetal prognosis was extremely poor for the abnormal fetus, selective feticide was a reasonable therapeutic option. Maternal symptoms resolved, allowing continuation of the pregnancy for 4 weeks before delivery of the healthy fetus. We maintain that selective termination induced a decrease in the release of substances involved in the physiopathology of preeclampsia, which allowed the continuation of the pregnancy with close follow-up. This report highlights the link between placental pathology and the disease process of preeclampsia and further supports selective termination as a reasonable management strategy in carefully selected cases of discordant twins.

Identifiants

pubmed: 31499281
pii: S2468-7847(19)30051-0
doi: 10.1016/j.jogoh.2019.101633
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101633

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Paul Guerby (P)

Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France; INSERM UMR 1048 I2MC, 31000, Toulouse, France. Electronic address: paul.guerby@gmail.com.

Agnès Sartor (A)

Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France.

Fabien Vidal (F)

Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France; University of Toulouse III, 31000, Toulouse, France.

Christophe Vayssière (C)

Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France; University of Toulouse III, 31000, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH